 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Incruse Ellipta |
| Other names | GSK573719A |
| License data | |
| Routes of administration | Inhalation (DPI) |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | ~89%[3] |
| Metabolism | Liver (CYP2D6) |
| Eliminationhalf-life | 11 hours |
| Excretion | Feces (58%) andurine (22%) |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.166.375 |
| Chemical and physical data | |
| Formula | C29H34BrNO2 |
| Molar mass | 508.500 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Umeclidinium bromide, sold under the brand nameIncruse Ellipta among others, is a long-actingmuscarinic antagonist approved for the maintenance treatment ofchronic obstructive pulmonary disease (COPD).[3] It is also approved for this indication in combination withvilanterol (asumeclidinium bromide/vilanterol),[5][6][7] and also as a triple-therapy combination asfluticasone furoate/umeclidinium bromide/vilanterol.[8]
It is on theWorld Health Organization's List of Essential Medicines.[9] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[10][11]
| Subsidiaries |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Predecessors, acquisitions | |||||||||
| Products |
| ||||||||
| People |
| ||||||||
| Litigation | |||||||||
| Other | |||||||||
 | Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it. |
